{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T16:00:07Z","timestamp":1795017607105,"version":"4.10.1"},"reference-count":72,"publisher":"Oxford University Press (OUP)","issue":"1119","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Membranous nephropathy (MN) is the most common cause of nephrotic syndrome in non-diabetic Caucasian adults over 40 years of age. It has an estimated incidence of 8\u201310 cases per 1 million. Fifty per cent of patients diagnosed with primary MN continue to have nephrotic syndrome and 30% of patients may progress to end-stage renal disease over 10 years. Although it was recognised as a distinct clinic-pathological entity in 1940s by immunofluorescence and electron microscopy, the pathogenesis and treatment have become more apparent only in the last decade. Discovery of M-type phospholipase A2 receptor (PLA2R) antibodies and thrombospondin type 1 domain-containing 7A antibodies has given new perspectives in understanding the pathogenesis of the disease process. Anti-PLA2R antibody is the first serologic marker that has promising evidence to be used as a tool to prognosticate the course of the disease. More importantly, therapeutic agents such as rituximab and adrenocorticotropic hormone analogues are the newer therapeutic options that should be considered in the therapy of primary MN.<\/jats:p>","DOI":"10.1136\/postgradmedj-2018-135729","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T19:01:19Z","timestamp":1548442879000},"page":"23-31","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":124,"title":["Primary membranous nephropathy: comprehensive review and historical perspective"],"prefix":"10.1093","volume":"95","clinical-trial-number":[{"clinical-trial-number":"nct03018535","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5392-6160","authenticated-orcid":false,"given":"Krishna C","family":"Keri","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Medical College of Wisconsin , Milwaukee, Wisconsin , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Blumenthal","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Medical College of Wisconsin , Milwaukee, Wisconsin , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Alabama , Birmingham, Alabama , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Beck","sequence":"additional","affiliation":[{"name":"Renal Section, Department of Medicine, Boston University School of Medicine , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tepsiri","family":"Chongkrairatanakul","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Medical College of Wisconsin , Milwaukee, Wisconsin , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,1,25]]},"reference":[{"key":"2023041306474318100_","volume-title":"Renal diseases","author":"Bell","year":"1946"},{"key":"2023041306474318100_","first-page":"313","article-title":"Nephrotic glomerulonephritis","volume":"33","author":"Jones","year":"1957","journal-title":"Am J Pathol"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrneph.2013.125","article-title":"Treatment of idiopathic membranous nephropathy","volume":"9","author":"Hofstra","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/ki.1983.170","article-title":"Pathologic differentiation between lupus and nonlupus membranous glomerulopathy","volume":"24","author":"Jennette","year":"1983","journal-title":"Kidney Int"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3181\/00379727-100-24736","article-title":"Production of nephrotic syndrome in rats by Freund\u2019s adjuvants and rat kidney suspensions","volume":"100","author":"Heymann","year":"1959","journal-title":"Exp Biol Med"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMoa012895","article-title":"Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies","volume":"346","author":"Debiec","year":"2002","journal-title":"N Engl J Med"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0165-6147(99)01300-0","article-title":"Receptors for a growing family of secreted phospholipases A2","volume":"20","author":"Lambeau","year":"1999","journal-title":"Trends Pharmacol Sci"},{"key":"2023041306474318100_","first-page":"502","article-title":"Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens. V. fixed glomerular antigens in the pathogenesis of heterologous immune complex glomerulonephritis","volume":"38","author":"Van Damme","year":"1978","journal-title":"Lab Invest"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1172\/JCI109248","article-title":"Experimental glomerulonephritis in the isolated perfused rat kidney","volume":"62","author":"Couser","year":"1978","journal-title":"J Clin Invest"},{"key":"2023041306474318100_","first-page":"57","article-title":"Distribution of IgG subclasses in membranous nephropathy","volume":"58","author":"Doi","year":"1984","journal-title":"Clin Exp Immunol"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1084\/jem.166.5.1351","article-title":"Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies","volume":"166","author":"Br\u00fcggemann","year":"1987","journal-title":"J Exp Med"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1002\/j.1460-2075.1988.tb03037.x","article-title":"Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies","volume":"7","author":"Dangl","year":"1988","journal-title":"Embo J"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1681\/ASN.2015080953","article-title":"Combined assessment of phospholipase A2 receptor autoantibodies and glomerular deposits in membranous nephropathy","volume":"27","author":"Qin","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2012030242","article-title":"Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy","volume":"23","author":"Hofstra","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/ki.2012.486","article-title":"Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy","volume":"83","author":"Kanigicherla","year":"2013","journal-title":"Kidney Int"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/ki.2010.34","article-title":"Membranous nephropathy: recent travels and new roads ahead","volume":"77","author":"Beck","year":"2010","journal-title":"Kidney Int"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/ndt\/gfr247","article-title":"An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis","volume":"26","author":"Hoxha","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMc1003066","article-title":"PLA2R autoantibodies and recurrent membranous nephropathy after transplantation","volume":"363","author":"Stahl","year":"2010","journal-title":"N Engl J Med"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1681\/ASN.2016070776","article-title":"A proposal for a serology-based approach to membranous nephropathy","volume":"28","author":"De Vriese","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med Overseas Ed"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.jprot.2011.05.021","article-title":"Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: alfa-enolase and borderline antigens","volume":"74","author":"Bruschi","year":"2011","journal-title":"J Proteomics"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1681\/ASN.2008121259","article-title":"Autoimmunity in membranous nephropathy targets aldose reductase and SOD2","volume":"21","author":"Prunotto","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1056\/NEJMoa1013792","article-title":"Early-childhood membranous nephropathy due to cationic bovine serum albumin","volume":"364","author":"Debiec","year":"2011","journal-title":"N Engl J Med"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1009742","article-title":"Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy","volume":"364","author":"Stanescu","year":"2011","journal-title":"N Engl J Med"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1681\/ASN.2017020178","article-title":"PLA2R and THSD7A: disparate paths to the same disease?","volume":"28","author":"Beck","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1681\/ASN.2016020114","article-title":"MHC Class II risk alleles and amino acid residues in idiopathic membranous nephropathy","volume":"28","author":"Cui","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/0002-9343(79)90486-8","article-title":"Long-term prognosis of idiopathic membranous glomerulonephritis. Study of 116 untreated patients","volume":"66","author":"Noel","year":"1979","journal-title":"Am J Med"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1681\/ASN.2005010028","article-title":"Management of membranous nephropathy: when and what for treatment","volume":"16","author":"Cattran","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1046\/j.1523-1755.2001.0590051983.x","article-title":"Idiopathic membranous glomerulonephritis","volume":"59","author":"Cattran","year":"2001","journal-title":"Kidney Int"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/ki.1992.374","article-title":"Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis","volume":"42","author":"Pei","year":"1992","journal-title":"Kidney Int"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/j.1523-1755.2004.00518.x","article-title":"Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan","volume":"65","author":"Shiiki","year":"2004","journal-title":"Kidney Int"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1084\/jem.91.1.1","article-title":"Localization of antigen in tissue cells: II. Improvements in a method for the detection of antigen by means of fluorescent antibody","volume":"91","author":"Coons","year":"1949","journal-title":"J Exp Med"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1084\/jem.106.5.649","article-title":"An electron microscope study of the glomerulus in nephrosis, glomerulonephritis, and lupus erythematosus","volume":"106","author":"Farquhar","year":"1957","journal-title":"J Exp Med"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0272-6386(12)80997-8","article-title":"IgG subclass deposits in glomeruli of lupus and nonlupus membranous nephropathies","volume":"23","author":"Haas","year":"1994","journal-title":"Am J Kidney Dis"},{"key":"2023041306474318100_","first-page":"295","article-title":"C4d as a diagnostic tool in membranous nephropathy","volume":"32","author":"Espinosa-Hern\u00e1ndez","year":"2012","journal-title":"Nefrologia"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/ndt\/14.4.881","article-title":"Glomerular deposition of mannose-binding lectin in human glomerulonephritis","volume":"14","author":"Lhotta","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"2023041306474318100_","first-page":"1391","article-title":"C4d immunohistochemical staining is a sensitive method to confirm immunoreactant deposition in formalin-fixed paraffin-embedded tissue in membranous glomerulonephritis","volume":"26","author":"Val-Bernal","year":"2011","journal-title":"Histol Histopathol"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJM199307083290203","article-title":"Prognosis of untreated patients with idiopathic membranous nephropathy","volume":"329","author":"Schieppati","year":"1993","journal-title":"N Engl J Med"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S0272-6386(99)70138-1","article-title":"Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy","volume":"33","author":"Laluck","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1523-1755.2004.00873.x","article-title":"Idiopathic membranous nephropathy: definition and relevance of a partial remission","volume":"66","author":"Troyanov","year":"2004","journal-title":"Kidney Int"},{"key":"2023041306474318100_","first-page":"48","article-title":"Predicting progression in membranous glomerulonephritis","volume":"7","author":"Cattran","year":"1992","journal-title":"Nephrol Dial Transplant"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/ki.1997.127","article-title":"Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications","volume":"51","author":"Cattran","year":"1997","journal-title":"Kidney Int"},{"key":"2023041306474318100_","first-page":"139","article-title":"KDIGO clinical practice guidelines for glomerulonephritis","year":"2012","journal-title":"KidneyInt"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1681\/ASN.2009080861","article-title":"Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy","volume":"21","author":"Polanco","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2215\/CJN.04250511","article-title":"Venous thromboembolism in patients with membranous nephropathy","volume":"7","author":"Lionaki","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM197912133012401","article-title":"A controlled study of short-term prednisone treatment in adults with membranous nephropathy. Collaborative study of the adult idiopathic nephrotic syndrome","volume":"301","author":"Coggins","year":"1979","journal-title":"N Engl J Med"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000182464","article-title":"Prednisone treatment of non-nephrotic patients with idiopathic membranous nephropathy. A prospective study","volume":"30","author":"Kobayashi","year":"1982","journal-title":"Nephron"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1056\/NEJM198901263200403","article-title":"A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy","volume":"320","author":"Cattran","year":"1989","journal-title":"N Engl J Med"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/oxfordjournals.qjmed.a068422","article-title":"The medical research council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulonephritis Working Party","volume":"74","author":"Cameron","year":"1990","journal-title":"Q J Med"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/0272-6386(95)90568-5","article-title":"A review of therapeutic studies of idiopathic membranous glomerulopathy","volume":"25","author":"Hogan","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1056\/NEJM198404123101503","article-title":"Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy","volume":"310","author":"Ponticelli","year":"1984","journal-title":"N Engl J Med"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/ki.1995.453","article-title":"A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy","volume":"48","author":"Ponticelli","year":"1995","journal-title":"Kidney Int"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/jnci\/87.7.524","article-title":"Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin\u2019s lymphoma","volume":"87","author":"Travis","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"366","DOI":"10.7326\/0003-4819-119-5-199309010-00003","article-title":"Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy","volume":"119","author":"Boumpas","year":"1993","journal-title":"Ann Intern Med"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/BF00869818","article-title":"Testicular function following cyclophosphamide treatment for childhood nephrotic syndrome: long-term follow-up study","volume":"4","author":"Bogdanovi\u0107","year":"1990","journal-title":"Pediatr Nephrol"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0015-0282(16)45622-0","article-title":"Suppression of spermatogenesis in patients with Beh\u00e7et\u2019s disease treated with cyclophosphamide and colchicine","volume":"36","author":"Fukutani","year":"1981","journal-title":"Fertil Steril"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/ki.1995.161","article-title":"A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian glomerulonephritis study group","volume":"47","author":"Cattran","year":"1995","journal-title":"Kidney Int"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1093\/ndt\/gfl360","article-title":"Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome","volume":"21","author":"Alexopoulos","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/sj.ki.5002215","article-title":"Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial","volume":"71","author":"Praga","year":"2007","journal-title":"Kidney Int"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MAJ.0b013e3181ca3a7d","article-title":"Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial","volume":"339","author":"Chen","year":"2010","journal-title":"Am J Med Sci"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1053\/j.ajkd.2008.04.013","article-title":"Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial","volume":"52","author":"Dussol","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1053\/j.ajkd.2007.05.015","article-title":"Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide","volume":"50","author":"Branten","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1681\/ASN.V7122518","article-title":"Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis)","volume":"7","author":"Kerjaschki","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"The Lancet"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.ki.5002628","article-title":"Rituximab treatment of idiopathic membranous nephropathy","volume":"73","author":"Fervenza","year":"2008","journal-title":"Kidney Int"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000430849","article-title":"A Multicenter randomized controlled trial of rituximab versus cyclosporine in the treatment of idiopathic membranous nephropathy (MENTOR)","volume":"130","author":"Fervenza","year":"2015","journal-title":"Nephron"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/ckj\/sfv075","article-title":"A European multicentre and open-label controlled randomized trial to evaluate the efficacy of sequential treatment with TAcrolimus-rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous nephropathy: the starmen study","volume":"8","author":"Rojas-Rivera","year":"2015","journal-title":"Clin Kidney J"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nrneph.2011.190","article-title":"The renaissance of corticotropin therapy in proteinuric nephropathies","volume":"8","author":"Gong","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.ajkd.2005.10.016","article-title":"A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy","volume":"47","author":"Ponticelli","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"2023041306474318100_","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/ndt\/gfu069","article-title":"A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar(R) Gel) in nephrotic syndrome due to idiopathic membranous nephropathy","volume":"29","author":"Hladunewich","year":"2014","journal-title":"Nephrol Dial Transplant"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/95\/1119\/23\/49809845\/postgradmedj-95-23.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/95\/1119\/23\/49809845\/postgradmedj-95-23.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T02:08:03Z","timestamp":1694570883000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/95\/1119\/23\/6984070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,1]]},"references-count":72,"journal-issue":{"issue":"1119","published-online":{"date-parts":[[2019,1,25]]},"published-print":{"date-parts":[[2019,1,1]]}},"URL":"https:\/\/doi.org\/10.1136\/postgradmedj-2018-135729","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,1]]},"published":{"date-parts":[[2019,1,1]]}}}